Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction (PEPCADNSTEMI)
Primary Purpose
Coronary Heart Disease, NSTEMI
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Stent
SeQuent(R) Please coated balloon
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Heart Disease focused on measuring drug coated balloon, NSTEMI
Eligibility Criteria
Inclusion Criteria:
- NSTEMI with
- Ischemic symptoms (angina pectoris) > 30 minutes
- Last symptoms within 72 hours before randomization
- Positive cardiac troponin T, I, or hs-Troponin above 99th percentile
- age > 18 years
- Identifiable culprit lesion without angiographic evidence of large thrombus with intended early PCI (treatment of up to two lesions allowed)
Exclusion Criteria:
- Cardiogenic shock
- ST-elevation myocardial infarction
- No identifiable culprit lesion, Indication for acute bypass surgery
- Comorbidity with limited life expectancy < 9-12 months
- Contraindication for treatment with heparin, ASA and thienopyridines
Sites / Locations
- Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Stent
DCB
Arm Description
Stent Implantation (DES or BMS), no further treatment
"DEBonly" strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection
Outcomes
Primary Outcome Measures
MACE
MACE means the occurence of cardiac death, reinfarction, or target lesion revascularization
Secondary Outcome Measures
Stent thrombosis (ARC
Mortality (cardiac and non-cardiac)
Reinfarction
target lesion revascularization
target vessel revascularization
any revascularization
Full Information
NCT ID
NCT01489449
First Posted
November 27, 2011
Last Updated
May 2, 2023
Sponsor
University Hospital, Saarland
1. Study Identification
Unique Protocol Identification Number
NCT01489449
Brief Title
Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
Acronym
PEPCADNSTEMI
Official Title
Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
December 2012 (Actual)
Primary Completion Date
June 23, 2018 (Actual)
Study Completion Date
June 23, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Saarland
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI.
Detailed Description
The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI. Primary efficacy endpoint will be MACE (cardiac mortality, reinfarction, and target lesion revascularization) after 9 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Heart Disease, NSTEMI
Keywords
drug coated balloon, NSTEMI
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
210 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stent
Arm Type
Placebo Comparator
Arm Description
Stent Implantation (DES or BMS), no further treatment
Arm Title
DCB
Arm Type
Active Comparator
Arm Description
"DEBonly" strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection
Intervention Type
Device
Intervention Name(s)
Stent
Intervention Description
bare metal stent implantation, any bare metal stent is allowed from different companies
Intervention Type
Combination Product
Intervention Name(s)
SeQuent(R) Please coated balloon
Other Intervention Name(s)
SeQuent(R) Please
Intervention Description
Angioplasty with Drug coated balloon (DCB)
Primary Outcome Measure Information:
Title
MACE
Description
MACE means the occurence of cardiac death, reinfarction, or target lesion revascularization
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Stent thrombosis (ARC
Time Frame
9 months, 3 years, 5 years
Title
Mortality (cardiac and non-cardiac)
Time Frame
9 months, 3 years, 5 years
Title
Reinfarction
Time Frame
9 months, 3 years, 5 years
Title
target lesion revascularization
Time Frame
9 months, 3 years, 5 years
Title
target vessel revascularization
Time Frame
9 months, 3 years, 5 years
Title
any revascularization
Time Frame
9 months, 3 years, 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
NSTEMI with
Ischemic symptoms (angina pectoris) > 30 minutes
Last symptoms within 72 hours before randomization
Positive cardiac troponin T, I, or hs-Troponin above 99th percentile
age > 18 years
Identifiable culprit lesion without angiographic evidence of large thrombus with intended early PCI (treatment of up to two lesions allowed)
Exclusion Criteria:
Cardiogenic shock
ST-elevation myocardial infarction
No identifiable culprit lesion, Indication for acute bypass surgery
Comorbidity with limited life expectancy < 9-12 months
Contraindication for treatment with heparin, ASA and thienopyridines
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruno Scheller, MD
Organizational Affiliation
Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
City
Homburg/Saar
State/Province
Saarland
ZIP/Postal Code
66421
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
We'll reach out to this number within 24 hrs